MUST

Mustang Bio is a clinical-stage biopharmaceutical company focused on developing next-generation cell and gene therapies for hematologic malignancies, solid tumors, and rare genetic diseases. The company's pipeline is built around chimeric antigen receptor T cell (CAR-T) therapies and lentiviral gene therapy technologies, often licensed from premier institutions like the City of Hope and St. Jude Children's Research Hospital. Their lead programs include MB-106, a CD20-targeted CAR-T for B-cell non-Hodgkin lymphoma, and MB-107, a gene therapy for X-linked severe combined immunodeficiency (X-SCID). Mustang Bio operates its own flexible manufacturing facility to support clinical development and potential commercialization of its complex cell-based medicines.